Equity Issuances

MAIA Biotechnology, Inc. issued 1,053,751 shares of common stock to certain accredited investors for $1.224 per share, aggregate $1,289,792.

“MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 1,053,751 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up to 1,053,751 shares of Common Stock, at a purchase price per Investor Share of $1.224, for an aggregate purchase price of approximately $1,289,792.”

North Haven Net REIT issued 76,438 Class IO shares and 5,990 Class E shares of common stock to a feeder vehicle primarily created to hold certain classes of the Company's common shares for aggregate consideration of approximately $1,565,000 and $123,000, respectively.

“As of December 1, 2025, North Haven Net REIT, a Maryland statutory trust (the “Company”), sold an aggregate of 76,438 Class IO shares and 5,990 Class E shares (the "Shares") (with the final number of Shares being determined on December 15, 2025) for aggregate consideration of approximately $1,565,000 and $123,000, respectively, based on the net asset value per share as of November 30, 2025, to a feeder vehicle primarily created to hold certain classes of the Company's common shares.”

VisionWave Holdings, Inc. issued 300,000 Pre-Funded Common Stock Purchase Warrants of warrant to BladeRanger Ltd. (Seller).

“(b) 300,000 Pre-Funded Common Stock Purchase Warrants (the “Initial PFWs”), each exercisable for one share of the Company's common stock”

VisionWave Holdings, Inc. issued 1,500,000 shares of the Company's common stock of common stock to BladeRanger Ltd. (Seller).

“the Company shall issue and deliver to the Seller (or its designee(s)): (a) 1,500,000 shares of the Company's common stock, $0.01 par value per share (the “Buyer Shares”)”

ACCURAY INC issued warrants to purchase 1,750,129 shares of Common Stock of warrant to certain lenders party to the Second Amendment.

“On December 12, 2025, concurrently with the Company’s entry into the Second Amendment, the Company issued to certain lenders party to the Second Amendment (i) warrants to purchase 3,062,726 shares of Common Stock, which warrants are exercisable on and after six months and one day after their Issue Date (as defined therein) and expire on December 15, 2032 and have an exercise price of $1.50 per share, subject to certain adjustments (the “Super Premium Warrants"), (ii) warrants to purchase 2,187,661 shares of Common Stock, which warrants are exercisable on and after six months and one day after their Issue Date (as defined therein) and expire on December 15, 2032 and have an exercise price of $1.25 per share, subject to certain adjustments (the “Premium Warrants"), and (iii) warrants to purchase 1,750,129 shares of Common Stock, which warrants are exercisable immediately, will expire on December 15, 2032 and have an exercise price of $0.01 per share (the “Penny Warrants")”

ACCURAY INC issued warrants to purchase 2,187,661 shares of Common Stock of warrant to certain lenders party to the Second Amendment.

“On December 12, 2025, concurrently with the Company’s entry into the Second Amendment, the Company issued to certain lenders party to the Second Amendment (i) warrants to purchase 3,062,726 shares of Common Stock, which warrants are exercisable on and after six months and one day after their Issue Date (as defined therein) and expire on December 15, 2032 and have an exercise price of $1.50 per share, subject to certain adjustments (the “Super Premium Warrants"), (ii) warrants to purchase 2,187,661 shares of Common Stock, which warrants are exercisable on and after six months and one day after their Issue Date (as defined therein) and expire on December 15, 2032 and have an exercise price of $1.25 per share, subject to certain adjustments (the “Premium Warrants")”

ACCURAY INC issued warrants to purchase 3,062,726 shares of Common Stock of warrant to certain lenders party to the Second Amendment.

“On December 12, 2025, concurrently with the Company’s entry into the Second Amendment, the Company issued to certain lenders party to the Second Amendment (i) warrants to purchase 3,062,726 shares of Common Stock, which warrants are exercisable on and after six months and one day after their Issue Date (as defined therein) and expire on December 15, 2032 and have an exercise price of $1.50 per share, subject to certain adjustments (the “Super Premium Warrants")”

Lexaria Bioscience Corp. issued 93,156 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC or its designees for exercise price of $1.6438 per share.

“number of Shares issued and sold on the Closing Date. The Placement Agent Warrants expire five years from the commencement of sales of the Offering and have an exercise price of $1.6438 per share of Common Stock armel, LLP, securities counsel to the Company, delivered an opinion as to the validity of the Shares, a copy of which is filed as Exhibit 5.1 to this”

Lexaria Bioscience Corp. issued up to 2,661,600 shares of Common Stock of warrant to certain institutional investors for exercise price of $1.19 per share.

“in a concurrent private placement, 2,661,600 common stock purchase warrants (the “Private Placement Warrants”), exercisable for an aggregate of up to 2,661,600 shares of Common Stock, at an exercise price of $1.19 per share of Common Stock”

Lexaria Bioscience Corp. issued 2,661,600 shares of common stock to certain institutional investors for $1.315 per share.

“the Company issued and sold to the investors (i) in a registered direct offering, 2,661,600 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.315 per share”

Vivakor, Inc. issued 15,427,519 shares of the Company’s common stock of common stock to seven non-affiliated accredited investors for $507,172.86 of the amounts due under the Lender Notes.

“Between December 10, 2025 and December 15, 2025, the Company received eight Notices of Conversion from the Lenders converting a total of $507,172.86 of the amounts due under the Lender Notes into 15,427,519 shares of the Company’s common stock (the “Lender Shares”).”

PERPETUA RESOURCES CORP. issued up to an aggregate of 370,000 Common Shares of warrant to a private, non-affiliated investor for exercisable at prices of $38.93, $43.26 and $47.59 per Common Share.

“second and third tranches expiring on the second and third year anniversaries, respectively, of issuance. The one-, two- and three-year Warrants will be exercisable at prices of $38.93, $43.26 and $47.59 per Common Share, respectively. The Warrants are subject to repurchase by the Company if the closing price of the Common Shares exceeds 130% of the respective”

PERPETUA RESOURCES CORP. issued 1,000,000 Common Shares of common stock to a private, non-affiliated investor for gross proceeds of $28.84 million.

“the Company agreed to sell and issue, for gross proceeds of $28.84 million (i) 1,000,000 Common Shares”

PERPETUA RESOURCES CORP. issued 138,696 common shares of common stock to Hatch Ltd. for aggregate gross proceeds of approximately $4 million, at a price of $28.84 per Common Share.

“the Company agreed to sell and issue, for aggregate gross proceeds of approximately $4 million, 138,696 common shares”

Streamex Corp. issued 2,443,750 shares of Common Stock of common stock to Terra Capital Natural Resources Fund Pty Ltd. for 12,671,297 shares of Empress common stock.

“the Company issued 2,443,750 shares of Common Stock to Purchaser in exchange for 12,671,297 shares of Empress common stock held by Purchaser.”

Nexentis Technologies Inc. issued 60,000 shares of common stock to consultants for various investor relations services.

“On December 15, 2025, N2OFF, Inc. (the “Company”) issued 60,000 shares of common stock pursuant to new consulting agreements to consultants in consideration of various investor relations services provided to the Company.”

Zoomcar Holdings, Inc. issued 1,000,000 shares of the Company's common stock of warrant to FirstFire Global Opportunities Fund, LLC for as additional consideration.

“pre-funded warrants to purchase 1,000,000 shares of the Company's common stock (the "Pre-Funded Warrants") as additional consideration”

Zoomcar Holdings, Inc. issued convertible note to FirstFire Global Opportunities Fund, LLC for original principal amount of $220,000.00.

“On December 10, 2025, Zoomcar Holdings, Inc. (the "Company") closed a Securities Purchase Agreement (the "Purchase Agreement") with FirstFire Global Opportunities Fund, LLC ("FirstFire"), in connection with a private placement offering of a convertible promissory note in the original principal amount of $220,000.00 (the "Note")”

Cadrenal Therapeutics, Inc. issued 414,748 shares of Common Stock of warrant to certain investors named on the signature pages for $10.60 per share.

“attached as Exhibit 4.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Terms of the Common Warrants The Common Warrants have an exercise price of $10.60 per share. The shares of Common Stock issuable upon the exercise of the Common Warrants are referred to as the “Common Warrant Shares.” The Common Warrants are”

Cadrenal Therapeutics, Inc. issued 207,374 shares of common stock to certain investors named on the signature pages for $10.85 per share.

“private placement, unregistered warrants (the “Common Warrants”) to purchase up to 414,748 shares of Common Stock (collectively, the “Offering”). The offering price per Share is $10.85. The Shares are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-277835) (the “Registration Statement”), a base prospectus included”

Overland Advantage issued 515 shares of preferred stock to accredited investors for $3,000 per share.

“On December 11, 2025, Overland Advantage (the “ Company ”) issued and sold 515 shares of its 12.0% Series A Cumulative Preferred Shares, par value $0.001 per share (the “ Series A Preferred Shares ”), for $3,000 per share to a select group of individual investors who are “accredited investors” within the meaning of Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended (the “ Securities Act ”).”

Blue Line Holdings, Inc. issued 100,000 common shares of common stock for $50,000.

“the Company will issue a total of 100,000 common shares and repay the loans in full”

Bluerock Acquisition Corp. issued an aggregate of 4,500,000 warrants of warrant to the Sponsor and the Underwriters for $1.00 per Private Placement Warrant.

“On December 12, 2025, simultaneously with the closing of the IPO, pursuant to the Private Placement Warrants Purchase Agreements, the Company completed the private sale of an aggregate of 4,500,000 warrants (the “ Private Placement Warrants ”) to the Sponsor and the Underwriters at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $4,000,000.”

3D SYSTEMS CORP issued 695,435 shares of common stock to J. Wood Capital Advisors LLC.

“On December 16, 2025, 3D Systems Corporation (the “Company”) issued 695,435 shares (the “JWCA Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), to J. Wood Capital Advisors LLC (“JWCA”) for services rendered in connection with the transactions contemplated by the Exchange and Consent Agreements (as defined below).”

VIAVI SOLUTIONS INC. issued 7,871,043 shares of common stock of common stock to limited number of existing holders of the Company's 1.625% Convertible Senior Notes due 2026 for $103.463 million aggregate principal amount of 1.625% Convertible Senior Notes due 2026.

“Pursuant to the Exchange Agreements, the Company has agreed to exchange $103.463 million aggregate principal amount of 2026 Notes held by the Transaction Participants for an aggregate of 7,871,043 shares (“Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock,” and such exchange, the “Exchange”) at a price per share of $17.88. The Exchange is expected to close on or about December 22, 2025, subject to customary closing conditions.”

UR-ENERGY INC issued $120.0 million aggregate principal amount of 4.75% Convertible Senior Notes due 2031 of convertible note to Initial Purchasers for approximately $114.8 million net proceeds.

“principal amount of notes that was granted to the initial purchasers of the offering of the notes (the “Initial Purchasers”). Net proceeds of the offering were approximately $114.8 million, after deducting Initial Purchasers’ discounts and commissions and estimated offering expenses payable by the Company. The Company expects to use the net proceeds from the”

Fortress Biotech, Inc. issued up to 600,000 shares of warrant to the lenders (Oaktree Fund Administration, LLC and lenders from time to time party thereto) for purchase price of $2.62 per share.

“the Company granted warrants to the lenders to purchase up to 600,000 shares of the Company’s common stock, par value $0.001 per share (“ Common Stock ”), at a purchase price of $2.62 per share (the “ Warrants ”)”

MIAMI INTERNATIONAL HOLDINGS, INC. issued 3,522,102 shares of common stock to certain of the Company's holders for $2,419,500 plus surrender of an aggregate of 698,521 shares of Common Stock pursuant to cashless exercise of warrants.

“Common Stock 12/12/2025 3,522,102 $2,419,500 plus surrender of an aggregate of 698,521 shares of Common Stock pursuant to cashless exercise of warrants”

MIAMI INTERNATIONAL HOLDINGS, INC. issued 317,787 shares of common stock for Conversion of a convertible promissory note in the principal amount of $5,000,000, plus accrued but unpaid interest thereunder at a price per share of $16.00.

“Common Stock 12/4/2025 317,787 Conversion of a convertible promissory note in the principal amount of $5,000,000, plus accrued but unpaid interest thereunder at a price per share of $16.00.”

MIAMI INTERNATIONAL HOLDINGS, INC. issued 7,483 shares of common stock for Conversion of $119,726 worth of accrued but unpaid interest under a convertible promissory note at a price per share of $16.00.

“Common Stock 10/1/2025 7,483 Conversion of $119,726 worth of accrued but unpaid interest under a convertible promissory note at a price per share of $16.00.”

Cottonwood Communities, Inc. issued 208,782 shares of Series 2025 Preferred Stock of preferred stock to accredited investors for $1,978,000 aggregate proceeds.

“During the period from December 5, 2025 through December 14, 2025, we issued and sold 208,782 shares of Series 2025 Preferred Stock in the Series 2025 Private Offering and received aggregate proceeds of $1,978,000.”

Momentus Inc. issued common stock.

“On December 3, 2025, the Board of Directors (the “Board”) of Momentus Inc., a Delaware corporation (the “Company”) approved a reverse stock split of the Company’s issued and outstanding shares of Class A Common Stock, $0.00001 par value per share (the “Common Stock”), at a ratio of 1-for-17.85 (the “Reverse Stock Split”). The Reverse Stock Split will be effective as of 5:00 p.m. Eastern Time on Wednesday, December 17, 2025 (the “Effective Date”), with the Common Stock trading on the Nasdaq Capital Market on a reverse-split adjusted basis under the Company’s existing trading symbol, “MNTS,” at the market open on Thursday, December 18, 2025.”

Jade Biosciences, Inc. issued 3,214,286 shares of common stock to the Purchaser for $14.00 per Share, aggregate gross proceeds approximately $45 million.

“On December 13, 2025, Jade Biosciences, Inc. (“Jade” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser named therein (the “Purchaser”), for the private placement (the “Private Placement”) of 3,214,286 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price of $14.00 per Share.”

Sky Quarry Inc. issued 699,977 shares of its common stock (Initial Shares) of common stock to LendSpark Corporation for settlement of $491,384.00 due and owing.

“pursuant to the terms of a settlement agreement entered into between the Company and LendSpark on December 1, 2025 (“Settlement Agreement”). The Settlement Agreement settled $491,384.00 due and owing from Foreland Refining Corporation, the Company’s wholly-owned subsidiary, to LendSpark pursuant to the terms of the business loan and security agreement dated May”

Humacyte, Inc. issued up to a number of shares of Common Stock, equal to the quotient of (i) up to $5,037,500... and (ii) the applicable Warrant Price of warrant to Avenue Venture Opportunities Fund II, L.P..

“On December 15, 2025, in connection with the Loan Agreement, the Company agreed to issue to Avenue a warrant (the “Warrant”) exercisable for up to a number of shares of Common Stock, equal to the quotient of (i) up to $5,037,500, consisting of (x) $3,412,500 and (y) upon the occurrence of the funding date of the Third Tranche Term Loan, $1,625,000, and (ii) the applicable Warrant Price”

Finance of America Companies Inc. issued 50,000 shares of preferred stock to Blue Owl for $1,000 per share for an aggregate purchase price $50.0 million.

“sale to Blue Owl of 50,000 shares of the Company’s Series A Convertible Perpetual Preferred Stock, par value $0.0001 per share (the “ Series A Preferred Stock ”), at a price of $1,000 per share for an aggregate purchase price $50.0 million (the “ Issuance ”). The closing of the Issuance is conditioned upon the satisfaction or waiver of customary closing”

AEON Biopharma, Inc. issued pre-funded warrants of warrant to Daewoong Pharmaceuticals, Co., LTD for in lieu of Common Stock shares exceeding 49.99% beneficial ownership.

“pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) in lieu of any shares of Common Stock that would result in Daewoong’s beneficial ownership of Common Stock exceeding 49.99%”

AEON Biopharma, Inc. issued $1,500,000 of convertible note to Daewoong Pharmaceuticals, Co., LTD for exchange of existing Convertible Notes.

“a new senior secured convertible note for $1,500,000 (the “New Convertible Note”)”

AEON Biopharma, Inc. issued up to 8,000,000 shares of warrant to Daewoong Pharmaceuticals, Co., LTD for exercise price of $1.09392 per share.

“warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share (the “Common Stock Warrant”).”

AEON Biopharma, Inc. issued approximately 23.1 million of common stock to Daewoong Pharmaceuticals, Co., LTD for exchange of Convertible Notes.

“On December 15, 2025, the Company and AEON Biopharma Sub, Inc., a Delaware corporation (the “AEON Sub”) entered into an Exchange Agreement (the “Exchange Agreement”) with Daewoong consistent with the terms of the Term Sheet pursuant to which the Convertible Notes held by Daewoong would be exchanged for (i) newly issued shares of Common Stock of the Company”

FibroBiologics, Inc. issued warrants to purchase up to 365,909 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC (placement agent) for services as placement agent.

“the Company will issue to the Placement Agent (or its designees) warrants to purchase 7.0% of the number of Shares of Common Stock sold in this the Registered Direct Offering (or warrants to purchase up to 365,909 shares of Common Stock), at an exercise price of $0.4125 per share (the "Placement Agent Warrants").”

FibroBiologics, Inc. issued 5,227,275 shares of Common Stock underlying Warrants of warrant to institutional investors for no additional consideration beyond the Purchase Agreement; exercise price $0.33 per share.

“5,227,275 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The price of each Share in the Registered Direct Offering is $0.33 (the “Offering Price”). Additionally, pursuant to the Purchase Agreement, the Company will issue to the Purchasers, in a concurrent private placement, warrants to purchase one”

FibroBiologics, Inc. issued 5,227,275 shares of common stock to institutional investors for gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses.

“approval as described below. The exercise price of the Warrants is $0.33 per share. The gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses payable by the Company. In addition, if the holders of the unregistered Warrants exercise such Warrants in full for”

Twelve Seas Investment Co III/Cayman issued 495,000 units of unit to Twelve Seas Sponsor LLC and Cohen and Company Capital Markets, a division of Cohen & Company Securities, LLC for $10.00 per Private Placement Unit for an aggregate purchase price of $4,950,000.

“Simultaneously with the closing of the IPO, pursuant to the Sponsor Private Placement Units Purchase Agreement and the Underwriters’ Private Placement Units Purchase Agreement, the Company completed the private sale of an aggregate of 495,000 units (the “Private Placement Units”) to the Sponsor and CCM at a price of $10.00 per Private Placement Unit for an aggregate purchase price of $4,950,000.”

ITHAX Acquisition Corp III issued 3,500,000 warrants of warrant to ITHAX Acquisition Sponsor III LLC for $1.00 per Sponsor Private Placement Warrant, generating gross proceeds to the Company of $3,500,000.

“Simultaneously with the closing of the IPO, (i) pursuant to the Sponsor Private Placement Warrants Purchase Agreement, the Company completed the private sale of an aggregate of 3,500,000 warrants (the "Sponsor Private Placement Warrants") to the Sponsor at a purchase price of $1.00 per Sponsor Private Placement Warrant, generating gross proceeds to the Company of $3,500,000”

Meshflow Acquisition Corp issued 5,333,333 warrants of warrant to Sponsor and Underwriters (Cantor Fitzgerald & Co., Odeon Capital Group, LLC) for $1.50 per Private Placement Warrant.

“On December 11, 2025, simultaneously with the closing of the IPO, pursuant to the Private Placement Warrants Purchase Agreements, the Company completed the private sale of an aggregate of 5,333,333 warrants (the “ Private Placement Warrants ”) to the Sponsor and the Underwriters at a purchase price of $1.50 per Private Placement Warrant, generating gross proceeds to the Company of $8,000,000.”

NATIONAL FUEL GAS CO issued 4,402,513 shares of common stock of common stock to certain investors for purchase price of $79.50 per share, gross proceeds of $350 million.

“agreed to sell to the Investors, in a private placement, shares of common stock (the “Offering”). Upon closing of the Offering, the Company expects to receive gross proceeds of $350 million, before deducting fees and expenses, resulting from the sale of 4,402,513 shares of common stock at a purchase price of $79.50 per share. The Offering is expected to close on”

RYVYL Inc. issued 50,000 shares of preferred stock to RTB Digital, Inc. for increased by $1,500,000 to aggregate of $6,500,000.

““Certificate of Designation”). Pursuant to the Amendment, such parties agreed to (i) increase the original purchase price for the 50,000 shares of Series C Preferred Stock by $1,500,000 to an aggregate of $6,500,000, to be paid at the signing of the Amendment by RTB to the Company, and (ii) increase the Stated Value (as defined in the Purchase Agreement) per”

My City Builders, Inc. issued 1,650,000 shares of its common stock of common stock to two accredited investors for $0.05 per share, for total gross proceeds of $82,500.

“On December 1, 2025, My City Builders, Inc. (the “Company”) issued an aggregate of 1,650,000 shares of its common stock at a purchase price of $0.05 per share, for total gross proceeds of $82,500, to two accredited investors in a private placement transaction.”

INTELLIGENT BIO SOLUTIONS INC. issued common stock.

“it will effect a 1-for-10 reverse split of its common stock, that will become effective at 11:59 pm (Eastern Time) on December 15, 2025”